David Gershenson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gershenson David M
Healthcare reform: it's time.
Klopp Ann H; Jhingran Anuja; Ramondetta Lois; Lu Karen; Gershenson David M; Eifel Patricia J
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Tung Celestine S; Mok Samuel C; Tsang Yvonne T M; Zu Zhifei; Song Huijuan; Liu Jinsong; Deavers Michael T; Malpica Anais; Wolf Judith K; Lu Karen H; Gershenson David M; Wong Kwong-Kwok
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Gershenson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Gershenson David M
Healthcare reform: it's time.
Gynecologic oncology 2009;115(2):181.
2009: Klopp Ann H; Jhingran Anuja; Ramondetta Lois; Lu Karen; Gershenson David M; Eifel Patricia J
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Gynecologic oncology 2009;115(1):6-11.
2009: Tung Celestine S; Mok Samuel C; Tsang Yvonne T M; Zu Zhifei; Song Huijuan; Liu Jinsong; Deavers Michael T; Malpica Anais; Wolf Judith K; Lu Karen H; Gershenson David M; Wong Kwong-Kwok
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(9):1243-50.
2009: Tao Xia; Sood Anil K; Deavers Michael T; Schmeler Kathleen M; Nick Alpa M; Coleman Robert L; Milojevic Ljiljana; Gershenson David M; Brown Jubilee
Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Gynecologic oncology 2009;114(3):431-6.
2009: Merritt William M; Danes Christopher G; Shahzad Mian M K; Lin Yvonne G; Kamat Aparna A; Han Liz Y; Spannuth Whitney A; Nick Alpa M; Mangala Lingegowda S; Stone Rebecca L; Kim Hye Sun; Gershenson David M; Jaffe Robert B; Coleman Robert L; Chandra Joya; Sood Anil K
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Cancer biology & therapy 2009;8(16):1596-603.
2009: Gershenson David M; Sun Charlotte C; Bodurka Diane; Coleman Robert L; Lu Karen H; Sood Anil K; Deavers Michael; Malpica Anais L; Kavanagh John J
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecologic oncology 2009;114(1):48-52.
2009: Schmeler Kathleen M; Vadhan-Raj Saroj; Ramirez Pedro T; Apte Sachin M; Cohen Lorenzo; Bassett Roland L; Iyer Revathy B; Wolf Judith K; Levenback Charles L; Gershenson David M; Freedman Ralph S
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
Gynecologic oncology 2009;113(2):210-5.
2009: Brown Jubilee; Sood Anil K; Deavers Michael T; Milojevic Ljiljana; Gershenson David M
Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?
Gynecologic oncology 2009;113(1):86-90.
2009: Gershenson David M
Letter from Houston "So what part of 'stable disease' do you not understand?".
Gynecologic oncology 2009;112(3):441.
2008: Schmeler Kathleen M; Gershenson David M
Low-grade serous ovarian cancer: a unique disease.
Current oncology reports 2008;10(6):519-23.
2008: Soliman Pamela T; Bassett Roland L; Wilson Erik B; Boyd-Rogers Stephanie; Schmeler Kathleen M; Milam Michael R; Gershenson David M; Lu Karen H
Limited public knowledge of obesity and endometrial cancer risk: what women know.
Obstetrics and gynecology 2008;112(4):835-42.
2008: Gershenson David M
SEER data: perspective at 10,000 feet.
Gynecologic oncology 2008;110(2):121-2.
2008: Ramirez Pedro T; Schmeler Kathleen M; Milam Michael R; Slomovitz Brian M; Smith Judith A; Kavanagh John J; Deavers Michael; Levenback Charles; Coleman Robert L; Gershenson David M
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Gynecologic oncology 2008;110(1):56-9.
2008: Sirisabya N; Li Y; Jaishuen A; Zheng H G; Gershenson D M; Kavanagh J J
Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):648-51.
2008: Han Liz Y; Fletcher Mavis S; Urbauer Diana L; Mueller Peter; Landen Charles N; Kamat Aparna A; Lin Yvonne G; Merritt William M; Spannuth Whitney A; Deavers Michael T; De Geest Koen; Gershenson David M; Lutgendorf Susan K; Ferrone Soldano; Sood Anil K
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3372-9.
2008: Lu Chunhua; Thaker Premal H; Lin Yvonne G; Spannuth Whitney; Landen Charles N; Merritt William M; Jennings Nicholas B; Langley Robert R; Gershenson David M; Yancopoulos George D; Ellis Lee M; Jaffe Robert B; Coleman Robert L; Sood Anil K
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
American journal of obstetrics and gynecology 2008;198(4):477.e1-9; discussion 477.e9-10.
2008: Schmeler Kathleen M; Sun Charlotte C; Bodurka Diane C; Deavers Michael T; Malpica Anais; Coleman Robert L; Ramirez Pedro T; Gershenson David M
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Gynecologic oncology 2008;108(3):510-4.
2008: Ramirez Pedro T; Landen Charles N; Coleman Robert L; Milam Michael R; Levenback Charles; Johnston Taren A; Gershenson David M
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Gynecologic oncology 2008;108(1):68-71.
2008: Stany Michael P; Bonome Tomas; Wamunyokoli Fred; Zorn Kristen; Ozbun Laurent; Park Dong-Choon; Hao Ke; Boyd Jeff; Sood Anil K; Gershenson David M; Berkowitz Ross S; Mok Samuel C; Birrer Michael J
Classification of ovarian cancer: a genomic analysis.
Advances in experimental medicine and biology 2008;622():23-33.
2007: Kamat Aparna A; Merritt William M; Coffey Donna; Lin Yvonne G; Patel Pooja R; Broaddus Russell; Nugent Elizabeth; Han Liz Y; Landen Charles N; Spannuth Whitney A; Lu Chunhua; Coleman Robert L; Gershenson David M; Sood Anil K
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7487-95.
2007: Gershenson David M
Fallopian tube cancer: stepchild or mother?
Gynecologic oncology 2007;107(3):386-7.
2007: Chi Dennis S; Ramirez Pedro T; Teitcher Jerrold B; Mironov Svetlana; Sarasohn Debra M; Iyer Revathy B; Eisenhauer Eric L; Abu-Rustum Nadeem R; Sonoda Yukio; Levine Douglas A; Brown Carol L; Aghajanian Carol; Gershenson David M; Hoskins William J; Hricak Hedvig; Barakat Richard R
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(31):4946-51.
2007: Lu Karen H; Schorge John O; Rodabaugh Kerry J; Daniels Molly S; Sun Charlotte C; Soliman Pamela T; White Kristin G; Luthra Rajyalakshmi; Gershenson David M; Broaddus Russell R
Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5158-64.
2007: Kim Tae Jin; Ravoori Murali; Landen Charles N; Kamat Aparna A; Han Liz Y; Lu Chunhua; Lin Yvonne G; Merritt William M; Jennings Nicholas; Spannuth Whitney A; Langley Robert; Gershenson David M; Coleman Robert L; Kundra Vikas; Sood Anil K
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Cancer research 2007;67(19):9337-45.
2007: Wong Kwong-Kwok; Lu Karen H; Malpica Anais; Bodurka Diane C; Shvartsman Hyun S; Schmandt Rosemarie E; Thornton Angela D; Deavers Michael T; Silva Elvio G; Gershenson David M
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2007;26(4):404-9.
2007: Saldivar J Salvador; Wu Xifeng; Follen Michele; Gershenson David
Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Gynecologic oncology 2007;107(1 Suppl 1):S56-71.
2007: Milam Michael R; Gu Jian; Yang Hushan; Celestino Joseph; Wu Weiguo; Horwitz Irwin B; Lacour Robin A; Westin Shannon N; Gershenson David M; Wu Xifeng; Lu Karen H
STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study.
Gynecologic oncology 2007;107(1):71-4.
2007: Landen Charles N; Lin Yvonne G; Immaneni Anand; Deavers Michael T; Merritt William M; Spannuth Whitney A; Bodurka Diane C; Gershenson David M; Brinkley William R; Sood Anil K
Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4098-104.
2007: Gershenson David M
Management of ovarian germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(20):2938-43.
2007: Gershenson David M; Miller Anna M; Champion Victoria L; Monahan Patrick O; Zhao Qianqian; Cella David; Williams Stephen D;
Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2792-7.
2007: Gershenson David M; Birrer Michael
Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer.
Gynecologic oncology 2007;106(1):1-3.
2007: Li Y F; Fu S; Hu W; Liu J H; Finkel K W; Gershenson D M; Kavanagh J J
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):739-63.
2007: Lin Yvonne G; Kunnumakkara Ajaikumar B; Nair Asha; Merritt William M; Han Liz Y; Armaiz-Pena Guillermo N; Kamat Aparna A; Spannuth Whitney A; Gershenson David M; Lutgendorf Susan K; Aggarwal Bharat B; Sood Anil K
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3423-30.
2007: Champion Victoria; Williams Stephen D; Miller Anna; Reuille Kristina M; Wagler-Ziner Kim; Monahan Patrick O; Zhao Qianqian; Gershenson David; Cella David;
Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;105(3):687-94.
2007: Shvartsman Hyun S; Sun Charlotte C; Bodurka Diane C; Mahajan Vrinda; Crispens Marta; Lu Karen H; Deavers Michael T; Malpica Anais; Silva Elvio G; Gershenson David M
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Gynecologic oncology 2007;105(3):625-9.
2007: Crotzer David R; Sun Charlotte C; Coleman Robert L; Wolf Judith K; Levenback Charles F; Gershenson David M
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Gynecologic oncology 2007;105(2):404-8.
2007: Crotzer David R; Wolf Judith K; Gano Jacalyn B; Gershenson David M; Levenback Charles
A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Gynecologic oncology 2007;105(2):399-403.
2007: Alvarez Ronald D; Gershenson David M
Integrating the Gynecologic Oncology Group and Gynecologic Cancer SPOREs--a square peg in a round hole or fits like a glove?
Gynecologic oncology 2007;105(1):1-2.
2007: Milam Michael R; Celestino Joseph; Wu Weiguo; Broaddus Russell R; Schmeler Kathleen M; Slomovitz Brian M; Soliman Pamela T; Gershenson David M; Wang Hong; Ellenson Lora H; Lu Karen H
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
American journal of obstetrics and gynecology 2007;196(3):247.e1-5.
2007: Lu Chunhua; Bonome Tomas; Li Yang; Kamat Aparna A; Han Liz Y; Schmandt Rosemarie; Coleman Robert L; Gershenson David M; Jaffe Robert B; Birrer Michael J; Sood Anil K
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
Cancer research 2007;67(4):1757-68.
2007: Kamat Aparna A; Kim Tae Jin; Landen Charles N; Lu Chunhua; Han Liz Y; Lin Yvonne G; Merritt William M; Thaker Premal H; Gershenson David M; Bischoff Farideh Z; Heymach John V; Jaffe Robert B; Coleman Robert L; Sood Anil K
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Cancer research 2007;67(1):281-8.
2007: Frumovitz Michael; Bodurka Diane C; Broaddus Russell R; Coleman Robert L; Sood Anil K; Gershenson David M; Burke Thomas W; Levenback Charles F
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer.
Gynecologic oncology 2007;104(1):100-3.
2007: Wong Kwong-Kwok; Gershenson David
The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.
Disease markers 2007;23(5-6):377-87.
2006: Landen Charles N; Merritt William M; Mangala Lingegowda S; Sanguino Angela M; Bucana Corazon; Lu Chunhua; Lin Yvonne G; Han Liz Y; Kamat Aparna A; Schmandt Rosemarie; Coleman Robert L; Gershenson David M; Lopez-Berestein Gabriel; Sood Anil K
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Cancer biology & therapy 2006;5(12):1708-13.
2006: Landen Charles N; Lu Chunhua; Han Liz Y; Coffman Karen T; Bruckheimer Elizabeth; Halder Jyotsnabaran; Mangala Lingegowda S; Merritt William M; Lin Yvonne G; Gao Changhou; Schmandt Rosemarie; Kamat Aparna A; Li Yang; Thaker Premal; Gershenson David M; Parikh Nila U; Gallick Gary E; Kinch Michael S; Sood Anil K
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Journal of the National Cancer Institute 2006;98(21):1558-70.
2006: Silva Elvio G; Gershenson David M; Malpica Anais; Deavers Michael
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
The American journal of surgical pathology 2006;30(11):1367-71.
2006: Morgan Robert J; Alvarez Ronald D; Armstrong Deborah K; Chen Lee-May; Copeland Larry; Fowler Jeff; Gaffney David K; Gershenson David; Greer Benjamin E; Johnston Carolyn; Lancaster Johnathan M; Lele Shashikant; Matulonis Ursula; Ozols Robert F; Remmenga Steven W; Sabbatini Paul; Soper John; Teng Nelson;
Ovarian cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(9):912-39.
2006: Merritt William M; Thaker Premal H; Landen Charles N; Deavers Michael T; Fletcher Mavis S; Lin Yvonne G; Han Liz Y; Kamat Aparna A; Schmandt Rosemarie; Gershenson David M; Kinch Michael S; Sood Anil K
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
Cancer biology & therapy 2006;5(10):1357-60.
2006: Kamat Aparna A; Bischoff Farideh Z; Dang Dianne; Baldwin Matthew F; Han Liz Y; Lin Yvonne G; Merritt William M; Landen Charles N; Lu Chunhua; Gershenson David M; Simpson Joe L; Sood Anil K
Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.
Cancer biology & therapy 2006;5(10):1369-74.
2006: Kamat Aparna A; Sood Anil K; Dang Dianne; Gershenson David M; Simpson Joe L; Bischoff Farideh Z
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.
Annals of the New York Academy of Sciences 2006;1075():230-4.
2006: Han Liz Y; Landen Charles N; Trevino Jose G; Halder Jyotsnabaran; Lin Yvonne G; Kamat Aparna A; Kim Tae-Jin; Merritt William M; Coleman Robert L; Gershenson David M; Shakespeare William C; Wang Yihan; Sundaramoorth Raji; Metcalf Chester A; Dalgarno David C; Sawyer Tomi K; Gallick Gary E; Sood Anil K
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Cancer research 2006;66(17):8633-9.
2006: Schmeler Kathleen M; Sun Charlotte C; Bodurka Diane C; White Kristin G; Soliman Pamela T; Uyei Anne R; Erlichman Julie L; Arun Banu K; Daniels Molly S; Rimes Susan A; Peterson Susan K; Slomovitz Brian M; Milam Michael R; Gershenson David M; Lu Karen H
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Obstetrics and gynecology 2006;108(3 Pt 1):515-20.
2006: Schmandt Rosemarie E; Bennett Marsha; Clifford Stephanie; Thornton Angela; Jiang Feng; Broaddus Russell R; Sun Charlotte C; Lu Karen H; Sood Anil K; Gershenson David M
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.
Cancer biology & therapy 2006;5(9):1136-41.
2006: Brewer Molly; Kirkpatrick Nathaniel D; Wharton J Taylor; Wang Jian; Hatch Kenneth; Auersperg Nelly; Utzinger Urs; Gershenson David; Bast Robert; Zou Changping
4-HPR modulates gene expression in ovarian cells.
International journal of cancer. Journal international du cancer 2006;119(5):1005-13.
2006: Wolf Judith K; Bodurka Diane C; Verschraegen Claire; Sun Charlotte C; Branham Donna; Jenkins Alfred D; Atkinson Neely; Gershenson David M
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Gynecologic oncology 2006;102(3):468-74.
2006: Halder Jyotsnabaran; Kamat Aparna A; Landen Charles N; Han Liz Y; Lutgendorf Susan K; Lin Yvonne G; Merritt William M; Jennings Nicholas B; Chavez-Reyes Arturo; Coleman Robert L; Gershenson David M; Schmandt Rosemarie; Cole Steven W; Lopez-Berestein Gabriel; Sood Anil K
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4916-24.
2006: Gershenson David M; Sun Charlotte C; Lu Karen H; Coleman Robert L; Sood Anil K; Malpica Anais; Deavers Michael T; Silva Elvio G; Bodurka Diane C
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
Obstetrics and gynecology 2006;108(2):361-8.
2006: Thaker Premal H; Han Liz Y; Kamat Aparna A; Arevalo Jesusa M; Takahashi Rie; Lu Chunhua; Jennings Nicholas B; Armaiz-Pena Guillermo; Bankson James A; Ravoori Murali; Merritt William M; Lin Yvonne G; Mangala Lingegowda S; Kim Tae Jin; Coleman Robert L; Landen Charles N; Li Yang; Felix Edward; Sanguino Angela M; Newman Robert A; Lloyd Mary; Gershenson David M; Kundra Vikas; Lopez-Berestein Gabriel; Lutgendorf Susan K; Cole Steven W; Sood Anil K
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Nature medicine 2006;12(8):939-44.
2006: Soliman Pamela T; Wu Diana; Tortolero-Luna Guillermo; Schmeler Kathleen M; Slomovitz Brian M; Bray Molly S; Gershenson David M; Lu Karen H
Association between adiponectin, insulin resistance, and endometrial cancer.
Cancer 2006;106(11):2376-81.
2006: Frumovitz Michael; Coleman Robert L; Gayed Isis W; Ramirez Pedro T; Wolf Judith K; Gershenson David M; Levenback Charles F
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer.
American journal of obstetrics and gynecology 2006;194(4):1186-93; discussion 1193-5.
2006: Coleman Robert L; Broaddus Russell R; Bodurka Diane C; Wolf Judith K; Burke Thomas W; Kavanagh John J; Levenback Charles F; Gershenson David M
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Gynecologic oncology 2006;101(1):126-31.
2006: Kamat Aparna A; Fletcher Mavis; Gruman Lynn M; Mueller Peter; Lopez Adriana; Landen Charles N; Han Liz; Gershenson David M; Sood Anil K
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1707-14.
2006: Han Liz Y; Landen Charles N; Kamat Aparna A; Lopez Adriana; Bender David P; Mueller Peter; Schmandt Rosemarie; Gershenson David M; Sood Anil K
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(5):755-61.
2006: Sood Anil K; Bhatty Robert; Kamat Aparna A; Landen Charles N; Han Liz; Thaker Premal H; Li Yang; Gershenson David M; Lutgendorf Susan; Cole Steven W
Stress hormone-mediated invasion of ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):369-75.
2006: Schmeler Kathleen M; Lynch Henry T; Chen Lee-may; Munsell Mark F; Soliman Pamela T; Clark Mary Beth; Daniels Molly S; White Kristin G; Boyd-Rogers Stephanie G; Conrad Peggy G; Yang Kathleen Y; Rubin Mary M; Sun Charlotte C; Slomovitz Brian M; Gershenson David M; Lu Karen H
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
The New England journal of medicine 2006;354(3):261-9.
2006: Frumovitz Michael; Gershenson David M
Fertility-sparing therapy for young women with endometrial cancer.
Expert review of anticancer therapy 2006;6(1):27-32.
2005: Soliman Pamela T; Broaddus Russell R; Schmeler Kathleen M; Daniels Molly S; Gonzalez Delia; Slomovitz Brian M; Gershenson David M; Lu Karen H
Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9344-50.
2005: Cheng Yee Chung; Saliba Rima M; Rondón Gabriela; Giralt Sergio A; Lu Karen H; Bodurka Diane C; Gershenson David M; Champlin Richard E; Ueno Naoto T
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation.
Haematologica 2005;90(12):1725-6.
2005: Bonome Tomas; Lee Ji-Young; Park Dong-Choon; Radonovich Mike; Pise-Masison Cindy; Brady John; Gardner Ginger J; Hao Ke; Wong Wing H; Barrett J Carl; Lu Karen H; Sood Anil K; Gershenson David M; Mok Samuel C; Birrer Michael J
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Cancer research 2005;65(22):10602-12.
2005: Schmeler Kathleen M; Soliman Pamela T; Sun Charlotte C; Slomovitz Brian M; Gershenson David M; Lu Karen H
Endometrial cancer in young, normal-weight women.
Gynecologic oncology 2005;99(2):388-92.
2005: Frumovitz Michael; Sun Charlotte C; Schover Leslie R; Munsell Mark F; Jhingran Anuja; Wharton J Taylor; Eifel Patricia; Bevers Therese B; Levenback Charles F; Gershenson David M; Bodurka Diane C
Quality of life and sexual functioning in cervical cancer survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7428-36.
2005: Marquez Rebecca T; Baggerly Keith A; Patterson Andrea P; Liu Jinsong; Broaddus Russell; Frumovitz Michael; Atkinson Edward N; Smith David I; Hartmann Lynn; Fishman David; Berchuck Andrew; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C; Lu Karen H
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6116-26.
2005: Stevens Tobey A; Brown Jubilee; Zander Dani S; Bevers Michael W; Gershenson David M; Ramondetta Lois M
Adult granulosa cell tumors of the ovary in two first-degree relatives.
Gynecologic oncology 2005;98(3):502-5.
2005: Brewer Molly; Wharton J Taylor; Wang Jian; McWatters Amanda; Auersperg Nelly; Gershenson David; Bast Robert; Zou Changping
In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Gynecologic oncology 2005;98(2):182-92.
2005: Kavanagh J J; Gershenson D M; Choi H; Lewis L; Patel K; Brown G L; Garcia A; Spriggs D R
Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(4):593-600.
2005: Lu Karen H; Gershenson David M
Update on the management of ovarian germ cell tumors.
The Journal of reproductive medicine 2005;50(6):417-25.
2005: Sood Anil K; Coleman Robert L; Wolf Judith K; Gershenson David M
Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.
Expert opinion on pharmacotherapy 2005;6(7):1269-75.
2005: Sood Anil K; Abu-Rustum Nadeem R; Barakat Richard R; Bodurka Diane C; Brown Jubilee; Donato Michele L; Poynor Elizabeth A; Wolf Judith K; Gershenson David M
Fifth International Conference on Ovarian Cancer: challenges and opportunities.
Gynecologic oncology 2005;97(3):916-23.
2005: Caudell Jimmy J; Deavers Michael T; Slomovitz Brian M; Lu Karen H; Broaddus Russell R; Gershenson David M; Ramondetta Lois M
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2005;13(2):167-70.
2005: Slomovitz B M; Ramondetta L M; Lee C M; Oh J C; Eifel P J; Jhingran A; Burke T W; Gershenson D M; Lu K H
Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(3):510-6.
2005: Brown Jubilee; Shvartsman Hyun S; Deavers Michael T; Ramondetta Lois M; Burke Thomas W; Munsell Mark F; Gershenson David M
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Gynecologic oncology 2005;97(2):489-96.
2005: See H T; Freedman R S; Kudelka A P; Burke T W; Gershenson D M; Tangjitgamol S; Kavanagh J J
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(2):209-16.
2005: Hartmann Lynn C; Lu Karen H; Linette Gerald P; Cliby William A; Kalli Kimberly R; Gershenson David; Bast Robert C; Stec James; Iartchouk Natalia; Smith David I; Ross Jeffrey S; Hoersch Sebastian; Shridhar Viji; Lillie James; Kaufmann Scott H; Clark Edwin A; Damokosh Andrew I
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2149-55.
2005: Soliman Pamela T; Oh Jonathan C; Schmeler Kathleen M; Sun Charlotte C; Slomovitz Brian M; Gershenson David M; Burke Thomas W; Lu Karen H
Risk factors for young premenopausal women with endometrial cancer.
Obstetrics and gynecology 2005;105(3):575-80.
2005: Lu Karen H; Dinh Mai; Kohlmann Wendy; Watson Patrice; Green Jane; Syngal Sapna; Bandipalliam Prathap; Chen Lee-May; Allen Brian; Conrad Peggy; Terdiman Jonathan; Sun Charlotte; Daniels Molly; Burke Thomas; Gershenson David M; Lynch Henry; Lynch Patrick; Broaddus Russell R
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.
Obstetrics and gynecology 2005;105(3):569-74.
2005: Rosen Daniel G; Yang Gong; Cai Kathy Qi; Bast Robert C; Gershenson David M; Silva Elvio G; Liu Jinsong
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):632-7.
2005: Gershenson David M
Fertility-sparing surgery for malignancies in women.
Journal of the National Cancer Institute. Monographs 2005;(34):43-7.
2004: Ramalingam Preetha; Malpica Anais; Silva Elvio G; Gershenson David M; Liu Jinsong L; Deavers Michael T
The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas.
The American journal of surgical pathology 2004;28(11):1499-505.
2004: Vidal Claudia I; Mintz Paul J; Lu Karen; Ellis Lee M; Manenti Luigi; Giavazzi Raffaella; Gershenson David M; Broaddus Russell; Liu Jinsong; Arap Wadih; Pasqualini Renata
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.
Oncogene 2004;23(55):8859-67.
2004: Sood Anil K; Coffin Jeremy E; Schneider Galen B; Fletcher Mavis S; DeYoung Barry R; Gruman Lynn M; Gershenson David M; Schaller Michael D; Hendrix Mary J C
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
The American journal of pathology 2004;165(4):1087-95.
2004: Slomovitz Brian M; Broaddus Russell R; Schmandt Rosemarie; Wu Weiguo; Oh Jonathan C; Ramondetta Lois M; Burke Thomas W; Gershenson David M; Lu Karen H
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Gynecologic oncology 2004;95(1):32-6.
2004: Tangjitgamol S; See H T; Manusirivithaya S; Levenback C F; Gershenson D M; Kavanagh J J
Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):804-14.
2004: Brown Jubilee; Shvartsman Hyun S; Deavers Michael T; Burke Thomas W; Munsell Mark F; Gershenson David M
The activity of taxanes in the treatment of sex cord-stromal ovarian tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(17):3517-23.
2004: Euscher Elizabeth D; Silva Elvio G; Deavers Michael T; Elishaev Esther; Gershenson David M; Malpica Anais
Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy.
The American journal of surgical pathology 2004;28(9):1217-23.
2004: Soliman Pamela T; Slomovitz Brian M; Broaddus Russell R; Sun Charlotte C; Oh Jonathan C; Eifel Patricia J; Gershenson David M; Lu Karen H
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.
Gynecologic oncology 2004;94(2):456-62.
2004: Wolf Judith K; Bodurka Diane C; Gano Jacalyn B; Deavers Michael; Ramondetta Lois; Ramirez Pedro T; Levenback Charles; Gershenson David M
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Gynecologic oncology 2004;94(2):442-8.
2004: Slomovitz Brian M; Broaddus Russell R; Burke Thomas W; Sneige Nour; Soliman Pamela T; Wu Weiguo; Sun Charlotte C; Munsell Mark F; Gershenson David M; Lu Karen H
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3126-32.
2004: Donato M L; Aleman A; Champlin R E; Saliba R M; Wharton J T; Burke T W; Bodurka D C; Bevers M W; Levenback C F; Wolf J K; Bast R C; Freedman R S; Ippoliti C; Brewer M; Gajewski J L; Gershenson D M
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.
Bone marrow transplantation 2004;33(12):1219-24.
2004: Lu Karen H; Patterson Andrea P; Wang Lin; Marquez Rebecca T; Atkinson Edward N; Baggerly Keith A; Ramoth Lance R; Rosen Daniel G; Liu Jinsong; Hellstrom Ingegerd; Smith David; Hartmann Lynn; Fishman David; Berchuck Andrew; Schmandt Rosemarie; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3291-300.
2004: Oh Jonathan C; Wu Weiguo; Tortolero-Luna Guillermo; Broaddus Russell; Gershenson David M; Burke Thomas W; Schmandt Rosemarie; Lu Karen H
Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(5):748-52.
2004: Sood Anil K; Fletcher Mavis S; Coffin Jeremy E; Yang Maria; Seftor Elisabeth A; Gruman Lynn M; Gershenson David M; Hendrix Mary J C
Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.
American journal of obstetrics and gynecology 2004;190(4):899-909.
2004: Nouriani Mory; Bahador Afshin; Berek Jonathan S; Cheng Joan P; Chi Dennis S; Cliby William A; Del Priore Giuseppe; Dodson Mark K; Duggan Bridgette D; Gershenson David M; Lentz Scott E; Penson Richard T; Robinson William R; Rodriguez Mildred; Roman Lynda D; Yu Mimi C; Zempolich Karen; Dubeau Louis
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(8):2681-6.
2004: Malpica Anais; Deavers Michael T; Lu Karen; Bodurka Diane C; Atkinson Edward N; Gershenson David M; Silva Elvio G
Grading ovarian serous carcinoma using a two-tier system.
The American journal of surgical pathology 2004;28(4):496-504.
2004: Apte Sachin M; Bucana Corazon D; Killion Jerald J; Gershenson David M; Fidler Isaiah J
Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines.
Gynecologic oncology 2004;93(1):78-86.
2004: Lee Christine M; Lo Hui-Wen; Shao Ru-Ping; Wang Shao-Chun; Xia Weiya; Gershenson David M; Hung Mien-Chie
Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy.
Cancer research 2004;64(5):1788-93.
2004: Eifel Patricia J; Winter Kathryn; Morris Mitchell; Levenback Charles; Grigsby Perry W; Cooper Jay; Rotman Marvin; Gershenson David; Mutch David G
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):872-80.
2004: Cohen Zvi R; Suki Dima; Weinberg Jeffrey S; Marmor Eric; Lang Frederick F; Gershenson David M; Sawaya Raymond
Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome.
Journal of neuro-oncology 2004;66(3):313-25.
2004: Baykal Atac; Thompson Jennifer A; Xu Xiao-Chun; Hahn William C; Deavers Michael T; Malpica Anais; Gershenson David M; Silva Elvio G; Liu Jinsong
In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues.
Oncology reports 2004;11(2):297-302.
2004: Donato Michele L; Levenback Charles; Gershenson David M; McMeekin Scott; Champlin Richard E
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.
Gynecologic oncology 2004;92(1):365-7.
2004: Liu Jinsong; Albarracin Constance T; Chang Ki-Hong; Thompson-Lanza Jennifer A; Zheng Wenxin; Gershenson David M; Broaddus Russell; Luthra Rajyalakshmi
Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2004;17(1):75-80.
2003: Slomovitz Brian M; Burke Thomas W; Eifel Patricia J; Ramondetta Lois M; Silva Elvio G; Jhingran Anuja; Oh Jonathan C; Atkinson E Neely; Broaddus Russell R; Gershenson David M; Lu Karen H
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
Gynecologic oncology 2003;91(3):463-9.
2003: Schmandt Rosemarie E; Broaddus Russell; Lu Karen H; Shvartsman Hyun; Thornton Angela; Malpica Anais; Sun Charlotte; Bodurka Diane C; Gershenson David M
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Cancer 2003;98(4):758-64.
2003: Shvartsman Hyun S; Lu Karen H; Lee John; Lillie Jim; Deavers Michael T; Clifford Stephanie; Wolf Judith K; Mills Gordon B; Bast Robert C; Gershenson David M; Schmandt Rosemarie
Overexpression of kallikrein 10 in epithelial ovarian carcinomas.
Gynecologic oncology 2003;90(1):44-50.
2003: Brown Jubilee; Broaddus Russell; Koeller Miriam; Burke Thomas W; Gershenson David M; Bodurka Diane C
Sarcomatoid carcinoma of the cervix.
Gynecologic oncology 2003;90(1):23-8.
2003: Siegel Barry A; Dehdashti Farrokh; Mutch David G; Podoloff Donald A; Wendt Richard; Sutton Gregory P; Burt Robert W; Ellis P Ron; Mathias Carla J; Green Mark A; Gershenson David M
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(5):700-7.
2003: Lee Christine M; Shvartsman Hyun; Deavers Michael T; Wang Shao-Chun; Xia Weiya; Schmandt Rosemarie; Bodurka Diane C; Atkinson E Neely; Malpica Anais; Gershenson David M; Hung Mien-Chie; Lu Karen H
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.
Gynecologic oncology 2003;88(3):363-8.
2003: Silva Elvio G; Deavers Michael T; Parlow A F; Gershenson David M; Malpica Anais
Calcifications in ovary and endometrium and their neoplasms.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2003;16(3):219-22.
2003: Jazaeri Amir A; Lu Karen; Schmandt Rosemarie; Harris Charles P; Rao Pulivarthi H; Sotiriou Christos; Chandramouli G V R; Gershenson David M; Liu Edison T
Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.
Molecular carcinogenesis 2003;36(2):53-9.
2003: Mills Gordon B; Fang Xianjun; Lu Yiling; Hasegawa Yutaka; Eder Astrid; Tanyi Janos; Tabassam Fazad Haq; Mao Muling; Wang Hongwei; Cheng Kwai Wa; Nakayama Yasuhisa; Kuo Wenlin; Erickson Jim; Gershenson David; Kohn Elise C; Jaffe Robert; Bast Robert C; Gray Joe
Specific keynote: molecular therapeutics in ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S88-92; discussion S93-6.
2003: Brewer Molly A; Johnson Karen; Follen Michele; Gershenson David; Bast Robert
Prevention of ovarian cancer: intraepithelial neoplasia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):20-30.
2003: Bodurka Diane C; Levenback Charles; Wolf Judith K; Gano Jacalyn; Wharton J Taylor; Kavanagh John J; Gershenson David M
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):291-7.
2003: Ramondetta Lois M; Bodurka Diane C; Tortolero-Luna Guillermo; Gordinier Mary; Wolf Judith K; Gershenson David M; Sciscione Anthony C
Mentorship and productivity among gynecologic oncology fellows.
Journal of cancer education : the official journal of the American Association for Cancer Education 2003;18(1):15-9.
2002: Munkarah A R; Jhingran A; Iyer R B; Wallace S; Eifel P J; Gershenson D; Burke T W
Utility of lymphangiography in the prediction of lymph node metastases in patients with cervical cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(6):755-9.
2002: Sun Charlotte C; Bodurka Diane C; Donato Michele L; Rubenstein Edward B; Borden Candice L; Basen-Engquist Karen; Munsell Mark F; Kavanagh John J; Gershenson David M
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
Gynecologic oncology 2002;87(1):118-28.
2002: Modesitt Susan C; Tortolero-Luna Guillermo; Robinson Jubilee B; Gershenson David M; Wolf Judith K
Ovarian and extraovarian endometriosis-associated cancer.
Obstetrics and gynecology 2002;100(4):788-95.
2002: Silva Elvio G; Ross Jennifer L; Gershenson David M; Deavers Michael T; Malpica Anais
Peritoneal lesions in guinea pigs treated with hormones.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2002;21(4):412-5.
2002: Castilleja Agapito; Carter Darrick; Efferson Clay L; Ward Nancy E; Kawano Kouichiro; Fisk Bryan; Kudelka Andrzej P; Gershenson David M; Murray James L; O'Brian Catherine A; Ioannides Constantin G
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(7):3545-54.
2002: Deavers Michael T; Gershenson David M; Tortolero-Luna Guillermo; Malpica Anais; Lu Karen H; Silva Elvio G
Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
The American journal of surgical pathology 2002;26(9):1129-41.
2002: Castilleja Agapito; Ward Nancy E; Epstein Richard B; Kudelka Andrzej P; Gershenson David M; Efferson Clay L; O'Brian Catherine A; Ioannides Constantin G
Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro.
Oncology reports 2002;9(5):929-35.
2002: Gershenson David M
Clinical management potential tumours of low malignancy.
Best practice & research. Clinical obstetrics & gynaecology 2002;16(4):513-27.
2002: Gershenson David M
Is micropapillary serous carcinoma for real?
Cancer 2002;95(4):677-80.
2002: Gershenson David M
Irinotecan in epithelial ovarian cancer.
Oncology (Williston Park, N.Y.) 2002;16(5 Suppl 5):29-31.
2002: Kuerer Henry M; Peoples George E; Sahin Aysegul A; Murray James L; Singletary S Eva; Castilleja Agapito; Hunt Kelly K; Gershenson David M; Ioannides Constantin G
Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(5):583-92.
2002: Dalrymple John L; Levenback Charles; Wolf Judith K; Bodurka Diane C; Garcia Michael; Gershenson David M
Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?
Gynecologic oncology 2002;85(2):356-61.
2002: Merchant S; Malpica A; Deavers M T; Czapar C; Gershenson D; Silva E G
Vessels within vessels in the myometrium.
The American journal of surgical pathology 2002;26(2):232-6.
2002: Silva Elvio G; Tornos Carmen; Malpica Anais; Deavers Michael T; Tortolero-Luna Guillermo; Gershenson David M
The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders.
International journal of surgical pathology 2002;10(1):33-9.
2002: Crispens Marta A; Bodurka Diane; Deavers Michael; Lu Karen; Silva Elvio G; Gershenson David M
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
Obstetrics and gynecology 2002;99(1):3-10.
2002: Herrera Carlos A; Xu Lei; Bucana Corazon D; Silva El Vio G; Hess Kenneth R; Gershenson David M; Fidler Isaiah J
Expression of metastasis-related genes in human epithelial ovarian tumors.
International journal of oncology 2002;20(1):5-13.
2001: Ramirez P T; Gershenson D M; Tortolero-Luna G; Ramondetta L M; Fightmaster D; Wharton J T; Wolf J K
Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Gynecologic oncology 2001;83(3):543-8.
2001: Gershenson D M
Why American women are not receiving state-of-the-art gynecologic cancer care.
Cancer journal (Sudbury, Mass.) 2001;7(6):450-7.
2001: Levenback C; Coleman R L; Burke T W; Bodurka-Bevers D; Wolf J K; Gershenson D M
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer.
Gynecologic oncology 2001;83(2):276-81.
2001: Che M; Tornos C; Deavers M T; Malpica A; Gershenson D M; Silva E G
Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001;20(4):323-8.
2001: Ortiz B H; Ailawadi M; Colitti C; Muto M G; Deavers M; Silva E G; Berkowitz R S; Mok S C; Gershenson D M
Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Cancer research 2001;61(19):7264-7.
2001: Ramirez P T; Ramondetta L M; Burke T W; Gershenson D M; Brewer M A
Metastatic uterine papillary serous carcinoma to the pericardium.
Gynecologic oncology 2001;83(1):135-7.
2001: Robinson J B; Singh D; Bodurka-Bevers D C; Wharton J T; Gershenson D M; Wolf J K
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Gynecologic oncology 2001;82(3):550-8.
2001: Donato M L; Gershenson D M; Wharton J T; Ippoliti C M; Aleman A S; Bodurka-Bevers D; Bevers M W; Burke T W; Levenback C F; Wolf J K; Freedman R S; Bast R C; Gajewski J L; Champlin R E
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Gynecologic oncology 2001;82(3):420-6.
2001: Brewer M; Utzinger U; Satterfield W; Hill L; Gershenson D; Bast R; Wharton J T; Richards-Kortum R; Follen M
Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(8):889-93.
2001: Malpica A; Deavers M T; Gershenson D; Tortolero-Luna G; Silva E G
Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential.
The American journal of surgical pathology 2001;25(8):988-96.
2001: Hortobagyi G N; Ueno N T; Xia W; Zhang S; Wolf J K; Putnam J B; Weiden P L; Willey J S; Carey M; Branham D L; Payne J Y; Tucker S D; Bartholomeusz C; Kilbourn R G; De Jager R L; Sneige N; Katz R L; Anklesaria P; Ibrahim N K; Murray J L; Theriault R L; Valero V; Gershenson D M; Bevers M W; Huang L; Lopez-Berestein G; Hung M C
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3422-33.
2001: Ramondetta L; Burke T W; Levenback C; Bevers M; Bodurka-Bevers D; Gershenson D M
Treatment of uterine papillary serous carcinoma with paclitaxel.
Gynecologic oncology 2001;82(1):156-61.
2001: Ramirez P T; Levenback C; Burke T W; Eifel P; Wolf J K; Gershenson D M
Sigmoid perforation following radiation therapy in patients with cervical cancer.
Gynecologic oncology 2001;82(1):150-5.
2001: Modesitt S C; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf J K
In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1765-72.
2001: Munkarah A; Levenback C; Wolf J K; Bodurka-Bevers D; Tortolero-Luna G; Morris R T; Gershenson D M
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Gynecologic oncology 2001;81(2):237-41.
2001: Basen-Engquist K; Bodurka-Bevers D; Fitzgerald M A; Webster K; Cella D; Hu S; Gershenson D M
Reliability and validity of the functional assessment of cancer therapy-ovarian.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1809-17.
2001: Castilleja A; Ward N E; O'Brian C A; Swearingen B; Swan E; Gillogly M A; Murray J L; Kudelka A P; Gershenson D M; Ioannides C G
Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Molecular and cellular biochemistry 2001;217(1-2):21-33.
2001: Brewer M; Utzinger U; Silva E; Gershenson D; Bast R C; Follen M; Richards-Kortum R
Fluorescence spectroscopy for in vivo characterization of ovarian tissue.
Lasers in surgery and medicine 2001;29(2):128-35.
2001: Utzinger U; Brewer M; Silva E; Gershenson D; Blast R C; Follen M; Richards-Kortum R
Reflectance spectroscopy for in vivo characterization of ovarian tissue.
Lasers in surgery and medicine 2001;28(1):56-66.
2000: Anderson B W; Peoples G E; Murray J L; Gillogly M A; Gershenson D M; Ioannides C G
Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4192-200.
2000: Anderson B W; Kudelka A P; Honda T; Pollack M S; Gershenson D M; Gillogly M A; Murray J L; Ioannides C G
Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides.
Cancer immunology, immunotherapy : CII 2000;49(9):459-68.
2000: Gordinier M E; Ramondetta L M; Parker L P; Wolf J K; Follen M; Gershenson D M; Bodurka-Bevers D
Survey of female gynecologic oncologists and fellows: balancing professional and personal life.
Gynecologic oncology 2000;79(2):309-14.
2000: Bodurka-Bevers D; Basen-Engquist K; Carmack C L; Fitzgerald M A; Wolf J K; de Moor C; Gershenson D M
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.
Gynecologic oncology 2000;78(3 Pt 1):302-8.
2000: Donato M L; Gershenson D; Ippoliti C; Wharton J T; Bast R C; Aleman A; Anderlini P; Gajewski J G; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin R E
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Bone marrow transplantation 2000;25(11):1137-40.
2000: Vang R; Medeiros L J; Silva E G; Gershenson D M; Deavers M
Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients.
The American journal of surgical pathology 2000;24(5):719-25.
2000: Lee T V; Anderson B W; Peoples G E; Castilleja A; Murray J L; Gershenson D M; Ioannides C G
Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
Oncology reports 2000;7(3):455-66.
2000: Lee T V; Kim D K; Peoples G E; Castilleja A; Murray J L; Gershenson D M; Ioannides C G
Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2000;20(4):391-401.
2000: Parker L P; Parker J R; Bodurka-Bevers D; Deavers M; Bevers M W; Shen-Gunther J; Gershenson D M
Paget's disease of the vulva: pathology, pattern of involvement, and prognosis.
Gynecologic oncology 2000;77(1):183-9.
2000: Morris R T; Gershenson D M; Silva E G; Follen M; Morris M; Wharton J T
Outcome and reproductive function after conservative surgery for borderline ovarian tumors.
Obstetrics and gynecology 2000;95(4):541-7.
2000: Vadhan-Raj S; Verschraegen C F; Bueso-Ramos C; Broxmeyer H E; Kudelkà A P; Freedman R S; Edwards C L; Gershenson D; Jones D; Ashby M; Kavanagh J J
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Annals of internal medicine 2000;132(5):364-8.
2000: Bodurka-Bevers D; Sun C C; Gershenson D M
Pharmacoeconomic considerations in treating ovarian cancer.
PharmacoEconomics 2000;17(2):133-50.
2000: Donato M L; Champlin R E; Wharton J T; Bodurka-Bevers D; Gershenson D
Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer.
European journal of gynaecological oncology 2000;21(3):241-4.
1999: Gershenson D M; Deavers M; Diaz S; Tortolero-Luna G; Miller B E; Bast R C; Mills G B; Silva E G
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4053-8.
1999: Gershenson D M; Morris M; Burke T W; Levenback C; Wolf J; Lee J J; Thall P F; Atkinson E N; Silva E G; Wharton J T
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Cancer 1999;86(11):2291-300.
1999: Wolf J K; Mills G B; Bazzet L; Bast R C; Roth J A; Gershenson D M
Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Gynecologic oncology 1999;75(2):261-6.
1999: Anderson L D; Hudson J M; Savary C A; Fisk B; Gershenson D M; Ioannides C G
HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells.
Cancer immunology, immunotherapy : CII 1999;48(7):401-10.
1999: Brewer M; Gershenson D M; Herzog C E; Mitchell M F; Silva E G; Wharton J T
Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2670-75.
1999: Morris M; Eifel P J; Lu J; Grigsby P W; Levenback C; Stevens R E; Rotman M; Gershenson D M; Mutch D G
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
The New England journal of medicine 1999;340(15):1137-43.
1999: Wolf J K; Mullen J; Eifel P J; Burke T W; Levenback C; Gershenson D M
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.
Gynecologic oncology 1999;73(1):35-41.
1999: Wolf J K; Kim T E; Fightmaster D; Bodurka D; Gershenson D M; Mills G; Wharton J T
Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus.
Gynecologic oncology 1999;73(1):27-34.
1999: Lin P S; Gershenson D M; Bevers M W; Lucas K R; Burke T W; Silva E G
The current status of surgical staging of ovarian serous borderline tumors.
Cancer 1999;85(4):905-11.
1998: Gershenson D M; Silva E G; Tortolero-Luna G; Levenback C; Morris M; Tornos C
Serous borderline tumors of the ovary with noninvasive peritoneal implants.
Cancer 1998;83(10):2157-63.
1998: Silva E G; Tornos C; Deavers M; Kaisman K; Gray K; Gershenson D
Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation.
Gynecologic oncology 1998;71(2):240-6.
1998: Gershenson D M; Burke T W; Morris M; Bast R C; Guaspari A; Hohneker J; Wharton J T
A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gynecologic oncology 1998;70(3):404-9.
1998: Morris M; Brader K R; Burke T W; Levenback C F; Gershenson D M
A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Gynecologic oncology 1998;70(2):215-8.
1998: Brader K R; Morris M; Levenback C; Levy L; Lucas K R; Gershenson D M
Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1879-84.
1998: Morris M; Brader K R; Levenback C; Burke T W; Atkinson E N; Scott W R; Gershenson D M
Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1094-8.
1998: Gershenson D M; Silva E G; Levy L; Burke T W; Wolf J K; Tornos C
Ovarian serous borderline tumors with invasive peritoneal implants.
Cancer 1998;82(6):1096-103.
1998: Silva E G; Tornos C; Zhuang Z; Merino M J; Gershenson D M
Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1998;17(1):1-6.
1997: Silva E G; Tornos C; Fritsche H A; el-Naggar A; Gray K; Ordonez N G; Luna M; Gershenson D
The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1997;10(9):879-83.
1997: Gershenson D M
Establishing SGO's strategic direction for the next millennium. Society of Gynecologic Oncologists.
Gynecologic oncology 1997;66(2):190-6.
1997: Gershenson D M; Baker V V; Price J E; Hung M C; El-Naggar A K; Tortolero-Luna G; Silva E G
Molecular profile of advanced-stage transitional cell carcinoma of the ovary.
American journal of obstetrics and gynecology 1997;177(1):120-5.
1997: Silva E G; Tornos C S; Malpica A; Gershenson D M
Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1997;10(7):663-7.
1997: Bicher A; Ault K; Kimmelman A; Gershenson D; Reed E; Liang B
Loss of heterozygosity in human ovarian cancer on chromosome 19q.
Gynecologic oncology 1997;66(1):36-40.
1997: Mooney J; Silva E; Tornos C; Gershenson D
Unusual features of serous neoplasms of low malignant potential during pregnancy.
Gynecologic oncology 1997;65(1):30-5.
1997: Morris M; Levenback C; Burke T W; Dejesus Y; Lucas K R; Gershenson D M
An outcomes management program in gynecologic oncology.
Obstetrics and gynecology 1997;89(4):485-92.
1997: Dimopoulos M A; Daliani D; Pugh W; Gershenson D; Cabanillas F; Sarris A H
Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy.
Gynecologic oncology 1997;64(3):446-50.
1997: Munkarah A R; Hallum A V; Morris M; Burke T W; Levenback C; Atkinson E N; Wharton J T; Gershenson D M
Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
Gynecologic oncology 1997;64(1):13-7.
1996: Segreti E M; Morris M; Levenback C; Lucas K R; Gershenson D M; Burke T W
Transverse colon urinary diversion in gynecologic oncology.
Gynecologic oncology 1996;63(1):66-70.
1996: Burke T W; Levenback C; Tornos C; Morris M; Wharton J T; Gershenson D M
Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study.
Gynecologic oncology 1996;62(2):169-73.
1996: Levenback C; Morris M; Burke T W; Gershenson D M; Wolf J K; Wharton J T
Groin dissection practices among gynecologic oncologists treating early vulvar cancer.
Gynecologic oncology 1996;62(1):73-7.
1996: Gershenson D M; Tortolero-Luna G; Malpica A; Baker V V; Whittaker L; Johnson E; Follen Mitchell M
Ovarian intraepithelial neoplasia and ovarian cancer.
Obstetrics and gynecology clinics of North America 1996;23(2):475-543.
1996: Gershenson D M; Morris M; Burke T W; Levenback C; Matthews C M; Wharton J T
Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Obstetrics and gynecology 1996;87(4):527-31.
1996: Segreti E M; Levenback C; Morris M; Lucas K R; Gershenson D M; Burke T W
A comparison of end and loop colostomy for fecal diversion in gynecologic patients with colonic fistulas.
Gynecologic oncology 1996;60(1):49-53.
1995: Reddoch J M; Burke T W; Morris M; Tornos C; Levenback C; Gershenson D M
Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme.
Gynecologic oncology 1995;59(2):221-5.
1995: Levenback C; Burke T W; Morris M; Malpica A; Lucas K R; Gershenson D M
Potential applications of intraoperative lymphatic mapping in vulvar cancer.
Gynecologic oncology 1995;59(2):216-20.
1995: Sweeten K M; Gershenson D M; Burke T W; Morris M; Levenback C; Silva E G
Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC).
Gynecologic oncology 1995;59(2):211-5.
1995: Eifel P J; Morris M; Burke T W; Levenback C; Gershenson D M
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva.
Gynecologic oncology 1995;59(1):51-6.
1995: Gershenson D M; Morris M; Burke T W; Levenback C; Kavanagh J J; Fromm G L; Silva E G; Warner D; Wharton J T
Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 1995;58(3):349-55.
1995: Miller B; Morris M; Levenback C; Burke T W; Gershenson D M
Pelvic exenteration for primary and recurrent vulvar cancer.
Gynecologic oncology 1995;58(2):202-5.
1995: Chuang L; Burke T W; Tornos C; Marino B D; Mitchell M F; Tortolero-Luna G; Levenback C; Morris M; Gershenson D M
Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes.
Gynecologic oncology 1995;58(2):189-93.
1995: Bicher A; Levenback C; Burke T W; Morris M; Warner D; DeJesus Y; Gershenson D M
Infusion site soft-tissue injury after paclitaxel administration.
Cancer 1995;76(1):116-20.
1995: Burke T W; Morris M; Roh M S; Levenback C; Gershenson D M
Perineal reconstruction using single gracilis myocutaneous flaps.
Gynecologic oncology 1995;57(2):221-5.
1995: Burke T W; Levenback C; Coleman R L; Morris M; Silva E G; Gershenson D M
Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy.
Gynecologic oncology 1995;57(2):215-20.
1995: Bicher A; Levenback C; Silva E G; Burke T W; Morris M; Gershenson D M
Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy.
Obstetrics and gynecology 1995;85(5 Pt 1):735-9.
1995: Morris M; Eifel P J; Burke T W; McNamara M M; Levenback C; Kavanagh J J; Gershenson D M
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy.
Gynecologic oncology 1995;57(1):72-8.
1995: Miller B; Morris M; Gershenson D M; Levenback C L; Burke T W
Intestinal fistulae formation following pelvic exenteration: a review of the University of Texas M. D. Anderson Cancer Center experience, 1957-1990.
Gynecologic oncology 1995;56(2):207-10.
1995: Marino B D; Burke T W; Tornos C; Chuang L; Mitchell M F; Tortolero-Luna G; Morris M; Gershenson D M
Staging laparotomy for endometrial carcinoma: assessment of peritoneal spread.
Gynecologic oncology 1995;56(1):34-8.
1994: Lehman E; Gershenson D M; Burke T W; Levenback C; Silva E G; Morris M
Salvage surgery for chemorefractory gestational trophoblastic disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2737-42.
1994: Burke T W; Morris M; Levenback C; Gershenson D M; Wharton J T
Closure of complex vulvar defects using local rhomboid flaps.
Obstetrics and gynecology 1994;84(6):1043-7.
1994: Gershenson D M
Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
Gynecologic oncology 1994;55(3 Pt 2):S62-72.
1994: Munkarah A; Gershenson D M; Levenback C; Silva E G; Messing M J; Morris M; Burke T W
Salvage surgery for chemorefractory ovarian germ cell tumors.
Gynecologic oncology 1994;55(2):217-23.
1994: Levenback C; Eifel P J; Burke T W; Morris M; Gershenson D M
Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix.
Gynecologic oncology 1994;55(2):206-10.
1994: Burke T W; Gershenson D M; Morris M; Stringer C A; Levenback C; Tortolero-Luna G; Baker V V
Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
Gynecologic oncology 1994;55(1):47-50.
1994: Levenback C; Burke T W; Gershenson D M; Morris M; Malpica A; Ross M I
Intraoperative lymphatic mapping for vulvar cancer.
Obstetrics and gynecology 1994;84(2):163-7.
1994: Gershenson D M
Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors.
Seminars in surgical oncology 1994;10(4):290-8.
1994: Morris M; Gershenson D M; Burke T W; Mitchell M F; Levenback C; Atkinson N; Wharton J T
A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix.
Gynecologic oncology 1994;53(2):234-8.
1994: Mulhollan T J; Silva E G; Tornos C; Guerrieri C; Fromm G L; Gershenson D
Ovarian involvement by serous surface papillary carcinoma.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1994;13(2):120-6.
1994: Levenback C; Gershenson D M; McGehee R; Eifel P J; Morris M; Burke T W
Enterovesical fistula following radiotherapy for gynecologic cancer.
Gynecologic oncology 1994;52(3):296-300.
1994: Gershenson D M
Primary cytoreduction for advanced epithelial ovarian cancer.
Obstetrics and gynecology clinics of North America 1994;21(1):121-40.
1993: Burke T W; Munkarah A; Kavanagh J J; Morris M; Levenback C; Tornos C; Gershenson D M
Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.
Gynecologic oncology 1993;51(3):397-400.
1993: Morris M; Mitchell M F; Silva E G; Copeland L J; Gershenson D M
Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix.
Gynecologic oncology 1993;51(2):193-6.
1993: Gershenson D M; Silva E G; Mitchell M F; Atkinson E N; Wharton J T
Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy.
American journal of obstetrics and gynecology 1993;168(4):1178-85; discussion 1185-7.
1993: Gershenson D M
Update on malignant ovarian germ cell tumors.
Cancer 1993;71(4 Suppl):1581-90.
1993: Gershenson D M; Mitchell M F; Atkinson N; Silva E G; Burke T W; Morris M; Kavanagh J J; Warner D; Wharton J T
Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience.
Cancer 1993;71(2 Suppl):638-43.
1993: Smith H O; Stringer C A; Kavanagh J J; Gershenson D M; Edwards C L; Wharton J T
Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy.
Gynecologic oncology 1993;48(1):11-5.
1992: Gershenson D M; Mitchell M F; Atkinson N; Silva E G; Kavanagh J J; Morris M; Burke T W; Warner D; Wharton J T
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.
Gynecologic oncology 1992;47(1):7-13.
1992: Morris M; Gershenson D M; Eifel P; Silva E G; Mitchell M F; Burke T W; Wharton J T
Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide.
Gynecologic oncology 1992;47(1):62-5.
1992: Levenback C; Burke T W; Silva E; Morris M; Gershenson D M; Kavanagh J J; Wharton J T
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Gynecologic oncology 1992;46(3):317-21.
1992: Grendys E C; Tang R A; Gershenson D M
Choroidal metastasis from primary ovarian carcinoma.
Gynecologic oncology 1992;46(2):251-4.
1992: Copeland L J; Silva E G; Gershenson D M; Morris M; Young D C; Wharton J T
Superficially invasive squamous cell carcinoma of the cervix.
Gynecologic oncology 1992;45(3):307-12.
1992: Matthews C M; Morris M; Burke T W; Gershenson D M; Wharton J T; Rutledge F N
Pelvic exenteration in the elderly patient.
Obstetrics and gynecology 1992;79(5 ( Pt 1)):773-7.
1992: Roman L D; Morris M; Eifel P J; Burke T W; Gershenson D M; Wharton J T
Reasons for inappropriate simple hysterectomy in the presence of invasive cancer of the cervix.
Obstetrics and gynecology 1992;79(4):485-9.
1992: Kelley J L; Burke T W; Tornos C; Morris M; Gershenson D M; Silva E G; Wharton J T
Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy.
Gynecologic oncology 1992;44(3):240-4.
1992: Watkin W; Silva E G; Gershenson D M
Mucinous carcinoma of the ovary. Pathologic prognostic factors.
Cancer 1992;69(1):208-12.
1991: Morris M; Gershenson D M; Burke T W; Wharton J T; Copeland L J; Rutledge F N
Splenectomy in gynecologic oncology: indications, complications, and technique.
Gynecologic oncology 1991;43(2):118-22.
1991: Eifel P J; Gershenson D M; Delclos L; Wharton J T; Peters L J
Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma.
International journal of radiation oncology, biology, physics 1991;21(4):1013-8.
1991: Jacob J H; Gershenson D M; Morris M; Copeland L J; Burke T W; Wharton J T
Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.
Gynecologic oncology 1991;42(2):146-50.
1991: Patton T J; Kavanagh J J; Delclos L; Wallace S; Haynie T P; Gershenson D M; Wharton J T; Bass S
Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina.
Gynecologic oncology 1991;42(1):54-9.
1991: Burke T W; Stringer C A; Morris M; Freedman R S; Gershenson D M; Kavanagh J J; Edwards C L
Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Gynecologic oncology 1991;40(3):264-7.
1991: Mitchell M F; Gershenson D M; Soeters R P; Eifel P J; Delclos L; Wharton J T
The long-term effects of radiation therapy on patients with ovarian dysgerminoma.
Cancer 1991;67(4):1084-90.
1991: Smiley L M; Burke T W; Silva E G; Morris M; Gershenson D M; Wharton J T
Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence.
Obstetrics and gynecology 1991;77(2):271-5.
1990: Morris M; Gershenson D M; Burke T W; Kavanagh J J; Silva E G; Wharton J T
Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1990;76(6):1020-4.
1990: Burke T W; Stringer C A; Gershenson D M; Edwards C L; Morris M; Wharton J T
Radical wide excision and selective inguinal node dissection for squamous cell carcinoma of the vulva.
Gynecologic oncology 1990;38(3):328-32.
1990: Stringer C A; Gershenson D M; Burke T W; Edwards C L; Gordon A N; Wharton J T
Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.
Gynecologic oncology 1990;38(3):305-8.
1990: Gershenson D M; Morris M; Cangir A; Kavanagh J J; Stringer C A; Edwards C L; Silva E G; Wharton J T
Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(4):715-20.
1990: Gershenson D M; Silva E G
Serous ovarian tumors of low malignant potential with peritoneal implants.
Cancer 1990;65(3):578-85.
1990: Fromm G L; Gershenson D M; Silva E G
Papillary serous carcinoma of the peritoneum.
Obstetrics and gynecology 1990;75(1):89-95.
1989: Turner D A; Gershenson D M; Atkinson N; Sneige N; Wharton A T
The prognostic significance of peritoneal cytology for stage I endometrial cancer.
Obstetrics and gynecology 1989;74(5):775-80.
1989: Crozier M A; Copeland L J; Silva E G; Gershenson D M; Stringer C A
Clear cell carcinoma of the ovary: a study of 59 cases.
Gynecologic oncology 1989;35(2):199-203.
1989: Morris M; Gershenson D M; Wharton J T; Copeland L J; Edwards C L; Stringer C A
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Gynecologic oncology 1989;34(3):334-8.
1989: Gordon A N; Gershenson D M; Copeland L J; Stringer C A; Morris M; Wharton J T
High-risk metastatic gestational trophoblastic disease: further stratification into two clinical entities.
Gynecologic oncology 1989;34(1):54-6.
1989: Gershenson D M; Kavanagh J J; Copeland L J; Stringer C A; Morris M; Wharton J T
Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.
Obstetrics and gynecology 1989;73(5 Pt 1):798-802.
1989: Morris M; Gershenson D M; Wharton J T
Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy.
Gynecologic oncology 1989;33(1):1-5.
1989: Gershenson D M; Wharton J T; Copeland L J; Stringer C A; Edwards C L; Kavanagh J J; Freedman R S
Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide.
Gynecologic oncology 1989;32(3):336-41.
1989: Robey S S; Silva E G; Gershenson D M; McLemore D; el-Naggar A; Ordonez N G
Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy.
Cancer 1989;63(5):839-47.
1989: Sahin A A; Silva E G; Landon G; Ordonez N G; Gershenson D M
Endometrial tissue in myometrial vessels not associated with menstruation.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1989;8(2):139-46.
1988: Larson D M; Copeland L J; Stringer C A; Gershenson D M; Malone J M; Edwards C L
Recurrent cervical carcinoma after radical hysterectomy.
Gynecologic oncology 1988;30(3):381-7.
1988: Copeland L J; Silva E G; Gershenson D M; Sneige N; Atkinson E N; Wharton J T
The significance of müllerian inclusions found at second-look laparotomy in patients with epithelial ovarian neoplasms.
Obstetrics and gynecology 1988;71(5):763-70.
1988: Kong J S; Peters L J; Wharton J T; Ang K K; Delclos L; Gershenson D M; Copeland L J; Edwards C L; Freedman R S; Saul P B
Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicity.
International journal of radiation oncology, biology, physics 1988;14(4):737-43.
1988: Gershenson D M
Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(2):270-5.
1988: Larson D M; Copeland L J; Malone J M; Stringer C A; Gershenson D M; Edwards C L
Diagnosis of recurrent cervical carcinoma after radical hysterectomy.
Obstetrics and gynecology 1988;71(1):6-9.
1987: Larson D M; Copeland L J; Gallager H S; Wharton J T; Gershenson D M; Rutledge F N
The significance of residual tumor after preoperative pelvic irradiation for stage II endometrial carcinoma.
Obstetrics and gynecology 1987;70(6):916-9.
1987: Gershenson D M; Copeland L J; Kavanagh J J; Stringer C A; Saul P B; Wharton J T
Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1987;70(5):765-9.
1987: Delmore J E; Wharton J T; Hamberger A D; Saul P B; Gershenson D M; Copeland L J
Preoperative radiotherapy for early endometrial carcinoma.
Gynecologic oncology 1987;28(1):34-40.
1987: Larson D M; Copeland L J; Gallager H S; Wharton J T; Gershenson D M; Edwards C L; Malone J M; Rutledge F N
Prognostic factors in stage II endometrial carcinoma.
Cancer 1987;60(6):1358-61.
1987: Larson D M; Malone J M; Copeland L J; Gershenson D M; Kline R C; Stringer C A
Ureteral assessment after radical hysterectomy.
Obstetrics and gynecology 1987;69(4):612-6.
1987: Larson D M; Copeland L J; Gallager H S; Gershenson D M; Freedman R S; Wharton J T; Kline R C
Nature of cervical involvement in endometrial carcinoma.
Cancer 1987;59(5):959-62.
1987: Larson D M; Stringer C A; Copeland L J; Gershenson D M; Malone J M; Rutledge F N
Stage IB cervical carcinoma treated with radical hysterectomy and pelvic lymphadenectomy: role of adjuvant radiotherapy.
Obstetrics and gynecology 1987;69(3 Pt 1):378-81.
1986: Gershenson D M; Wharton J T; Kline R C; Larson D M; Kavanagh J J; Rutledge F N
Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity.
Cancer 1986;58(12):2594-9.
1986: Gershenson D M; del Junco G; Silva E G; Copeland L J; Wharton J T; Rutledge F N
Immature teratoma of the ovary.
Obstetrics and gynecology 1986;68(5):624-9.
1986: Gordon A N; Kavanagh J J; Gershenson D M; Saul P B; Copeland L J; Stringer C A
Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease.
Cancer 1986;58(7):1407-10.
1986: Gershenson D M; Copeland L J; del Junco G; Edwards C L; Wharton J T; Rutledge F N
Second-look laparotomy in the management of malignant germ cell tumors of the ovary.
Obstetrics and gynecology 1986;67(6):789-93.
1986: Hancock K C; Copeland L J; Gershenson D M; Saul P B; Wharton J T; Rutledge F N
Urinary conduits in gynecologic oncology.
Obstetrics and gynecology 1986;67(5):680-4.
1986: Gershenson D M; Kavanagh J J; Copeland L J; Del Junco G; Cangir A; Saul P B; Stringer C A; Edwards C L; Wharton J T
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin.
Cancer 1986;57(9):1731-7.
1986: Copeland L J; Sneige N; Gershenson D M; Saul P B; Stringer C A; Seski J C
Adenoid cystic carcinoma of Bartholin gland.
Obstetrics and gynecology 1986;67(1):115-20.
1985: Gershenson D M; Copeland L J; Kavanagh J J; Cangir A; Del Junco G; Saul P B; Stringer C A; Freedman R S; Edwards C L; Wharton J T
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide.
Cancer 1985;56(12):2756-61.
1985: Copeland L J; Sneige N; Stringer C A; Gershenson D M; Saul P B; Kavanagh J J
Alveolar rhabdomyosarcoma of the female genitalia.
Cancer 1985;56(4):849-55.
1985: Copeland L J; Gershenson D M; Saul P B; Sneige N; Stringer C A; Edwards C L
Sarcoma botryoides of the female genital tract.
Obstetrics and gynecology 1985;66(2):262-6.
1985: Kavanagh J J; Copeland L J; Gershenson D M; Saul P B; Wharton J T; Rutledge F N
Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.
Gynecologic oncology 1985;21(2):211-4.
1985: Copeland L J; Sneige N; Ordonez N G; Hancock K C; Gershenson D M; Saul P B; Kavanagh J J
Endodermal sinus tumor of the vagina and cervix.
Cancer 1985;55(11):2558-65.
1985: Smith S T; Seski J C; Copeland L J; Gershenson D M; Edwards C L; Herson J
Surgical management of irradiation-induced small bowel damage.
Obstetrics and gynecology 1985;65(4):563-7.
1985: Gordon A N; Gershenson D M; Copeland L J; Saul P B; Kavanagh J J; Edwards C L
High-risk metastatic gestational trophoblastic disease.
Obstetrics and gynecology 1985;65(4):550-6.
1984: Gershenson D M; Del Junco G; Copeland L J; Rutledge F N
Mixed germ cell tumors of the ovary.
Obstetrics and gynecology 1984;64(2):200-6.
1984: Miller B E; Copeland L J; Hamberger A D; Gershenson D M; Saul P B; Herson J; Rutledge F N
Carcinoma of the cervical stump.
Gynecologic oncology 1984;18(1):100-8.
1983: Copeland L J; Wharton J T; Rutledge F N; Gershenson D M; Seski J C; Herson J
Role of "third-look" laparotomy in the guidance of ovarian cancer treatment.
Gynecologic oncology 1983;15(2):145-53.
1983: Gershenson D M; Del Junco G; Herson J; Rutledge F N
Endodermal sinus tumor of the ovary: the M. D. Anderson experience.
Obstetrics and gynecology 1983;61(2):194-202.
1981: Gershenson D M; Wharton J T; Herson J; Edwards C L; Rutledge F N
Single-agent cis-platinum therapy for advanced ovarian cancer.
Obstetrics and gynecology 1981;58(4):487-96.
1981: Seski J C; Edwards C L; Copeland L J; Gershenson D M
Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Obstetrics and gynecology 1981;58(3):361-3.
1981: Seski J C; Edwards C L; Gershenson D M; Copeland L J
Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer.
Obstetrics and gynecology 1981;58(1):88-91.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

David Gershenson

Research Profile (preview)

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of David Gershenson (preview)

All Publications